Zoom imageColorectal carcinomas frequently develop from protruding growths in the intestine known as polyps.
Bayer Schering Pharma has initiated an international Phase III trial to evaluate its investigational compound regorafenib for the treatment of patients with metastatic colorectal cancer (CRC) which has progressed after standard therapies. Regorafenib is a novel, oral multi-kinase inhibitor that targets various tumor growth enzymes. Says Bayer Schering Pharma Management Board member Dr. Kemal Malik: “There are very few treatment options available to patients with colorectal cancer whose disease has progressed following treatment with existing therapies.”